Breaks Categories: News

TuesdayJun 27, 2023 11:03 am

BioMedNewsBreaks – iHealthScreen Announces Successful Fundraising Efforts, Reaches $150K on StartEngine

iHealthScreen, an artificial intelligence (“AI”)-based health-screening company, announced that it has raised $150,000 on StartEngine. An AI-driven, HIPAA-compliant medtech company, iHealthScreen uses AI to screen for retinal diseases, stroke and heart disease and prevent blindness, deaths and disabilities. In addition to the $150,000 raised on StartEngine, iHealthScreen has raised more than $3 million in seed and NIH funding. The company offers investors a unique opportunity to capitalize on AI-driven, health-screening software developed by medical professionals. According to the company, testing for certain diseases and conditions can be cost prohibitive, and primary care providers often don't have resources to do more…

Continue Reading

MondayJun 26, 2023 3:41 pm

BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of IL-17 Nanobody Phase 2 Trial

MoonLake (NASDAQ: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, has announced positive top-line results from its global phase 2 MIRA trial. The trial (“M1095-HS-201”) evaluated the efficacy and safety of the Nanobody(R) Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”). MoonLake’s shares closed nearly $20.00 up on the day to $45.95 following the recent news. “As part of our efforts to elevate outcomes for patients, we set an ambitious goal for our Nanobody(R) Sonelokimab to ‘meet or beat’ the best results shown in pivotal-like trials of competitors,” said Jorge Santos da Silva, PhD, founder…

Continue Reading

MondayJun 26, 2023 3:02 pm

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Now Included in Russell Microcap(R) Index

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, is joining the Russell Microcap(R) Index, effective today. The company announced that it will be included following the conclusion of the 2023 Russell indexes annual reconstitution. According to the announcement, Russell Microcap Index membership is in effective for one year and consists of automatic inclusion in the appropriate growth and value style indexes. The announcement observed that objective, market-capitalization rankings as well as style attributes are primarily used by FTSE Russell to determine membership of index members. “NextPlat's inclusion in the Russell Microcap Index is important recognition of the value of our global…

Continue Reading

FridayJun 23, 2023 2:26 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug Administration’s approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is expected to continue increasing at a compound annual growth rate of 4% over the next decade. Meanwhile,…

Continue Reading

FridayJun 23, 2023 12:12 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a video published by InvestmentPitch Media. FSD Pharma recently entered into a non-binding letter of intent with 1319741 B.C. Ltd., an unlisted reporting issuer, which will be renamed Celly Nutrition Inc. FSD Pharma and Celly Nutrition (“Celly Nu”) intend to enter into a definitive licensing and loan agreement whereby FSD will provide Celly Nu an exclusive license to commercialize products developed using FSD’s IP for alcohol misuse…

Continue Reading

ThursdayJun 22, 2023 11:46 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (“EB”). According to the announcement, of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in…

Continue Reading

ThursdayJun 22, 2023 10:50 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering

Clene (NASDAQ: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, recently announced the pricing of an underwritten public offering. The offering consists of 50,000,000 shares of its common stock and two tranches of warrants (each warrant to purchase one share of common stock) at a combined public offering price of $0.80 for each share of common stock and accompanying warrant. From the expected $40 million in gross proceeds from the offering, Clene intends to use the net proceeds, together with its existing…

Continue Reading

WednesdayJun 21, 2023 2:21 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development…

Continue Reading

WednesdayJun 21, 2023 10:53 am

BioMedNewsBreaks – Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering

Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, recently announced the pricing of an underwritten public offering of common stock. The company is selling 2,538,071 shares of its common stock in the offering, each at a price to the public of $1.97, for aggregate gross proceeds of approximately $5.0 million. In addition, Bone Biologics has granted the underwriters an over-allotment option, exercisable for a period of 45 days from the date of the underwriting agreement for the offering, to purchase up to an additional 253,807 common shares. Subject to customary conditions, the offering was expected…

Continue Reading

TuesdayJun 20, 2023 12:08 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced its entry into a non-binding letter of intent. The agreement, dated June 19, 2023, is with 1319741 B.C. Ltd., which will be renamed “Celly Nutrition Inc.” (“Celly Nu”), an unlisted reporting issuer, and sets forth the basic terms and conditions upon which Celly Nu will be granted exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology designed to accelerate alcohol detoxification. FSD Pharma will…

Continue Reading